search
Back to results

An Open-label Trial of Clevidipine for Controlled Hypotension During Spinal Fusion

Primary Purpose

Neuromuscular Scoliosis

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Clevidipine
Sponsored by
Nationwide Children's Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Neuromuscular Scoliosis

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Spinal fusion for neuromuscular scoliosis.

Exclusion Criteria:

  • Allergy to dihydropyridine calcium channel antagonists
  • Allergy to soy or eggs
  • Non-neuromuscular causes of scoliosis
  • Disorders of lipid metabolism (clevidipine is in a lipid base)

Sites / Locations

  • Nationwide Children's Hospital

Arms of the Study

Arm 1

Arm Type

Active Comparator

Arm Label

Clevidipine

Arm Description

Outcomes

Primary Outcome Measures

Time to Achieve Target MAP
The time between start of clevidipine infusion and patient reaching target mean arterial pressure (MAP) at 55-65 mmHg

Secondary Outcome Measures

Full Information

First Posted
June 8, 2012
Last Updated
February 3, 2015
Sponsor
Nationwide Children's Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT01645111
Brief Title
An Open-label Trial of Clevidipine for Controlled Hypotension During Spinal Fusion
Official Title
An Open-label Trial of Clevidipine for Controlled Hypotension During Spinal Fusion
Study Type
Interventional

2. Study Status

Record Verification Date
February 2015
Overall Recruitment Status
Completed
Study Start Date
June 2012 (undefined)
Primary Completion Date
December 2013 (Actual)
Study Completion Date
December 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Nationwide Children's Hospital

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The current study would prospectively evaluate the dosing requirements, efficacy and safety of clevidipine for controlled hypotension during spinal surgery in the pediatric population. As the investigators currently have projects underway which include those patients having scoliosis surgery for idiopathic scoliosis, this trial would include only those undergoing scoliosis surgery for neuromuscular disease.
Detailed Description
This would basically be an observational study without a significant change in our current practice. There would be no change in the standard and usual anesthetic care including premedication, anesthetic induction, intraoperative anesthetic management, and intraoperative monitoring. Our usual anesthetic routine includes: Intravenous or oral premedication with midazolam Inhalational or intravenous induction based on the preference of the patient Facilitation of endotracheal intubation with a dose of rocuronium with placement of intraoperative monitors including an arterial cannula Maintenance anesthesia to include desflurane titrated to maintain the bispectral index at 40-60, fentanyl 2-4 µg/kg followed by a remifentanil infusion to maintain the mean arterial pressure at 55-65 mmHg. Tranexamic acid to limit intraoperative bleeding As needed, agent to control blood pressure to maintain the MAP at 55-65 mmHg if remifentanil in doses up to 0.3 µg/kg/min are ineffective. As needed, clevidipine will be started at 1 µg/kg/min and titrated up in 1 µg/kg/min every 1-2 minutes to achieve an MAP at 55-65mmHg. Vital signs including heart rate will be recorded every 1 minute until the target MAP is achieved and then at 15 minute increments after that.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Neuromuscular Scoliosis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Clevidipine
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Clevidipine
Primary Outcome Measure Information:
Title
Time to Achieve Target MAP
Description
The time between start of clevidipine infusion and patient reaching target mean arterial pressure (MAP) at 55-65 mmHg
Time Frame
First 30 minutes of infusion

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Spinal fusion for neuromuscular scoliosis. Exclusion Criteria: Allergy to dihydropyridine calcium channel antagonists Allergy to soy or eggs Non-neuromuscular causes of scoliosis Disorders of lipid metabolism (clevidipine is in a lipid base)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Joseph Tobias, MD
Organizational Affiliation
Nationwide Children's Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Nationwide Children's Hospital
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43205
Country
United States

12. IPD Sharing Statement

Learn more about this trial

An Open-label Trial of Clevidipine for Controlled Hypotension During Spinal Fusion

We'll reach out to this number within 24 hrs